查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496018

全球兒科疫苗市場－2024年至2029年預測

Global Pediatric Vaccine Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 130 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

兒科疫苗市場預計將從 2022 年的 309.2 億美元增至 2029 年的 495.5 億美元，預測期內複合年成長率為 7.03%。

兒童疫苗接種和免疫接種是先進醫療保健的重要組成部分，儘管許多疫苗很常見，但不同地區的疫苗接種可能略有不同。這些疫苗透過幫助兒童在接觸疾病之前培養防禦能力和免疫力，幫助保護他們免受各種疾病的侵害。透過加強人體的一般或自然防禦，疫苗中所含的抗體使身體能夠快速有效地對抗危險的感染疾病。

疫苗是在很小的時候就接種的。兒童的抵抗力和免疫系統對於對抗嚴重和感染疾病至關重要，但它們仍在發展階段，增加了感染疾病的風險。這一成長可能是由於公眾對疫苗接種重要性的認知不斷提高。此外，政府和非政府對疫苗開拓的補貼增加可能會在未來幾年進一步發展兒科疫苗產業。

市場促進因素：

  • 結合疫苗領域的增加預計將推動兒科疫苗的成長。

CDC提案所有 2 歲以下兒童接種肺炎鏈球菌結合疫苗（PCV13 或 Prevnar13）。

由於免疫反應的改善、兒童極端感染疾病的避免、疫苗接種計劃的納入以及免疫規劃的製定，預計聯合免疫部分將擴大。由於弱抗原和載體蛋白的結合，結合疫苗對新生兒和幼兒非常有效。它在預防兒童常見的極端感染疾病方面發揮著重要作用，例如 B 型流感嗜血桿菌 (Hib)、肺炎鏈球菌和腦膜炎奈瑟菌。

由於預防兒童感染疾病的重要性，許多國家已將結合免疫納入其小兒科免疫計畫。世界衛生組織和聯合國兒童基金會等組織的全球健康工作和舉措優先考慮兒童健康，並倡導廣泛使用抗體。公眾意識的提高、進步、政府對研究和開發的支持增加以及改善公共衛生所需的兒童免疫接種的整體優先次序將推動結合疫苗產業的擴張。

  • 政府加大力度改善初級醫療保健基礎設施也支持了市場。

不僅在已開發國家，開發中國家也努力提高兒科免疫率，預計將對全球兒科疫苗產業的擴張產生重大影響。此外，兒童流感、百日咳、牙關緊閉、白喉等感染疾病和非感染疾病的流行也是導致該市場快速擴張的主要因素。

此外，由於印度等國家的人口成長，世界各地的兒童數量也在增加。此外，根據聯合國兒童基金會2020年的資料，印度每天有67,385名嬰兒出生，佔世界出生人數的六分之一。因此，新生兒和兒科人口的成長預計將在預測期內推動全球兒科疫苗產業的發展。

北美地區預計將佔據全球兒科疫苗市場的很大佔有率。大規模的研發支出、容易獲得最先進的醫療設施、重要的市場競爭對手的存在以及公眾對醫療疾病的高度認知被認為是最大的影響因素。

由於加強政府促進醫療保健的政策，預計亞太地區在預測期內將以最高的複合年成長率成長，特別是在印度和中國等成長中的經濟體。例如，印度政府有效且成功的脊髓灰質炎疫苗接種計劃是該國最成功的兒童疫苗接種計劃之一。此外，為了降低兒童死亡率，印度於 2021 年 12 月擴大了肺炎鏈球菌聯合疫苗接種覆蓋範圍，將 PCV13 疫苗納入其中。

主要進展：

  • 2024 年 2 月 - Fapon 與印尼國營製藥公司 Bio Pharma 簽署了一份合作備忘錄，以加強該國的醫療創新。該合作夥伴關係旨在開發生物藥品、技術、醫療設備和體外診斷，重點是醫療保健的在地化。其目的是促進協同合作，促進醫療創新，並推動印尼的醫療保健產業。東南亞最大的疫苗製造公司BioPharma將利用兩家公司的優勢加強醫療服務，為全球診斷和醫療生態系統做出貢獻。
  • 2024 年 1 月 - Endeavour Health 透過社區投資基金 (CIF) 向羅莎琳德富蘭克林大學的社區護理連結 (CCC) 提供 175 萬美元。 CCC 增加了工作人員，將流感疫苗供應增加了一倍，並提供免費健康檢查、免疫接種和健康教育計劃。 CCC 也租賃了電動車，增加了 COVID-19、鏈球菌性感染疾病、尿道感染和流感的快速檢測套組，並增加了流感疫苗的購買。這種財政支持具有變革性，使 CCC 能夠提供更多的健康資源、教育以及與社區機構的聯繫，以解決健康的社會決定因素。
  • 2023 年 9 月 -食品藥物管理局對輝瑞-BioNTech COVID-19 疫苗（2023-2024）進行了修訂。這種單價疫苗針對 SARS-CoV-2 的 omicron 變體 XBB.1.5，已被批准用於 6 個月至 11 歲個體的所有劑量，以預防 COVID-19。它被核准用於尚未接種疫苗的人、已接種一劑輝瑞-BioNTech COVID-19 疫苗的人以及已接種兩到四劑輝瑞-BioNTech COVID-19 疫苗的人。
  • 2022 年 6 月 - GSK 獲得 FDA核准Priorix，一種麻疹、流行性腮腺炎和德國麻疹疫苗，適用於 12 個月及以上的個體。該疫苗已在 100 多個國家獲得批准，迄今已注射了 8 億多劑疫苗。然而，最近的麻疹疫情爆發可能會逆轉幾十年來根除麻疹的努力。疾病預防控制中心的研究表明，兒童的免疫記錄可能不是最新的，因為訂購的疫苗訂單減少了，入幼兒園的兒童也減少了。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球兒科疫苗市場：依疫苗類型

  • 介紹
  • 單價
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 多效價的
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章全球兒科疫苗市場：依技術分類

  • 介紹
  • 減毒活疫苗
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 去活化疫苗
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 次單位疫苗、重組疫苗、多醣體疫苗、結合疫苗
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 類毒素疫苗
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章 全球兒科疫苗市場：依應用分類

  • 介紹
  • 感染疾病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 癌症
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 過敏
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章全球兒科疫苗市場：按地區

  • 介紹
  • 北美洲
    • 按疫苗類型
    • 依技術
    • 按用途
    • 按國家/地區
  • 南美洲
    • 按疫苗類型
    • 依技術
    • 按用途
    • 按國家/地區
  • 歐洲
    • 按疫苗類型
    • 依技術
    • 按用途
    • 按國家/地區
  • 中東/非洲
    • 按疫苗類型
    • 依技術
    • 按用途
    • 按國家/地區
  • 亞太地區
    • 按疫苗類型
    • 依技術
    • 按用途
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • GlaxoSmithKline Plc
  • Merck Sharp & Dohme Corp.
  • Sanofi
  • Pfizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • AstraZeneca
  • Seqirus（CSL Limited）
簡介目錄
Product Code: KSI061611923

The global pediatric vaccine market is expected to expand at a CAGR of 7.03% during the projected period to attain US$49.550 billion by 2029, up from US$30.920 billion in 2022.

Vaccination and immunization of children are vital constituents of advanced medication and may change marginally depending upon the area, indeed in spite of the fact that numerous vaccines are common. These vaccines offer assistance to safeguard children from different illnesses by supporting them to grow defense and immunity (assurance) that protects them against illnesses prior to they come into contact with them. By fortifying the human body's common protections i.e. natural defenses, the antibodies in the vaccines allow the human body to battle dangerous infections quickly and more competently.

Vaccines are begun at a very early age. Children are at expanded risk for infectious illnesses since their resistant mechanisms and immune systems are still in the developing phase the essential resistances to battle severe diseases and infections. The boost may be credited to the increasing public awareness among individuals concerning the significance of immunization. An increment in government and non-government subsidizing for the investigation and advancement of vaccines will moreover increase the industry for pediatric vaccines in the years ahead, at the same time, the high price of the vaccine could obstruct the market development in the coming years.

Market Drivers:

  • An increase in the conjugate vaccine segment is anticipated to surge the pediatric vaccine growth.

Conjugate vaccines are chemically attached antigens to carrier proteins, converting them into T-dependent antigens that elicit robust immune responses in infants and adults The CDC suggests the schedule direction for pneumococcal conjugate immunization (PCV13 or Prevnar13) for all children that are under two years of age.

The conjugate immunization segment's extension is anticipated due to improved immune reaction, avoidance of extreme infections in children, incorporated vaccine plans, and development of inoculation programs. Conjugate immunizations are profoundly successful in newborn children and young children because of their weak antigen's combination with a carrier protein. They play a pivotal part in anticipating extreme infectious illnesses commonly influencing children, such as Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, and Neisseria meningitidis.

Numerous nations have consolidated conjugate immunizations into their pediatric immunization plans, reflecting their significance in avoiding infections amid early childhood. Global health well-being activities and initiatives by organizations, like WHO and UNICEF, prioritize health of child and advocate for the broad utilization of antibodies. growing awareness among the public, progressing advancement, in R&D supportive drive by the government, and the general prioritization of pediatric immunization as a necessity for improved public well-being is anticipated to drive expansion within the conjugate vaccine industry.

  • Rising efforts of the government to upgrade their primary healthcare infrastructure would propel the market.

Developing as well as developed nations are taking action to improve admittance to pediatric immunization, which is anticipated to emphatically affect the worldwide pediatric vaccine industry expansion. Besides, the predominance of various infections, such as flu, pertussis, lockjaw, and diphtheria, among other infectious diseases as well as non-infectious diseases in children is however another major cause driving this market exponentially.

Also, the rising populace of nations such as India is expanding up to the population of children all over the globe. Further, as per UNICEF data for 2020, 67,385 babies are born in India each day, which accounts for one-sixth of the world's childbirth. Thus, the rising newborn child and children populace is anticipated to drive the worldwide pediatric vaccine industry amid the projected period.

The global pediatric vaccines market is expected to be dominated by the North American region, which is expected to hold a significant share of the pediatric vaccine market. Large-scale R&D expenditures, easy access to cutting-edge medical facilities, the presence of significant market competitors, and the general public's high degree of medical disease awareness may all contribute to the biggest proportion.

Due to increased government policies to promote healthcare, especially in growing economies like India and China, Asia-Pacific is anticipated to expand at the greatest CAGR over the forecast period. For instance, India's effective and successful polio vaccination drive presented by the government of India is one of the foremost successful pediatric vaccination drives within the nation. Moreover, with the intention to lower childhood mortality, India expanded its Pneumococcal Conjugate immunization scope in December 2021 to incorporate the PCV13 immunization.

Key Development:

  • February 2024- Fapon and Indonesian state-owned pharmaceutical company Bio Farma signed a memorandum of understanding to strengthen medical innovations in the country. The partnership aims to develop biological medicines, technologies, medical devices, and IVD solutions, with a focus on healthcare localization. The goal is to foster synergistic collaboration, drive medical innovation, and boost the healthcare industry in Indonesia. Bio Farma, the largest vaccine manufacturer in Southeast Asia, leverages both companies' strengths to enhance healthcare services and contribute to the global diagnostics and medical treatment ecosystem.
  • January 2024- Endeavor Health provided $1.75 million to Rosalind Franklin University's Community Care Connection (CCC) through its Community Investment Fund (CIF). The CCC has increased staff, doubled flu vaccine availability, and provided free health screenings, vaccinations, and health education programs. The CCC also leased electric vehicles, acquired more rapid-test kits for COVID-19, strep throat, urinary tract infections, and the flu, and increased flu vaccine purchases. The financial support is transformative, enabling the CCC to provide more health resources, education, and connections to community agencies to address social determinants of health.
  • September 2023- The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) was amended by the Food and Drug Administration to include the 2023-2024 formula. The monovalent vaccine, corresponding to the Omicron variant XBB.1.5 of SARS-CoV-2, was authorized for all doses administered to individuals aged 6 months to 11 years to prevent COVID-19. It was approved for unvaccinated individuals, those who have received one dose of any Pfizer BioNTech COVID-19 Vaccine, and those who have received two to four doses.
  • June 2022- GSK received FDA approval for Priorix, a vaccine for measles, mumps, and rubella, for individuals aged 12 months and older. With vaccination licenses in more than 100 countries, more than 800 million doses have been administered. Nevertheless, breakouts in recent times have undone decades of measles eradication. According to CDC research, there has been a decrease in the ordering of vaccines and fewer kids starting kindergarten, which raises the possibility that kids' vaccination records are out of current.

Market Segmentation:

The Global Pediatric Vaccine Market is segmented and analyzed as below:

By Vaccine Type

  • Monovalent
  • Multivalent

By Technology

  • Live-attenuated vaccines
  • Inactivated vaccines
  • Subunit, recombinant, polysaccharide, and conjugate vaccines
  • Toxoid vaccines
  • Others

By Application

  • Infectious Diseases
  • Cancer
  • Allergies

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL PEDIATRIC VACCINE MARKET BY VACCINE TYPE

  • 5.1. Introduction
  • 5.2. Monovalent
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Multivalent
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL PEDIATRIC VACCINE MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Live-attenuated vaccines
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Inactivated vaccines
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Subunit, recombinant, polysaccharide, and conjugate vaccines
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Toxoid vaccines
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL PEDIATRIC VACCINE MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Infectious Diseases
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Cancer
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Allergies
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL PEDIATRIC VACCINE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Vaccine Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Vaccine Type
    • 8.3.2. By Technology
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Vaccine Type
    • 8.4.2. By Technology
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. United Kingdom
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Vaccine Type
    • 8.5.2. By Technology
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. Israel
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Vaccine Type
    • 8.6.2. By Technology
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. Japan
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Indonesia
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Others
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. GlaxoSmithKline Plc
  • 10.2. Merck Sharp & Dohme Corp.
  • 10.3. Sanofi
  • 10.4. Pfizer Inc.
  • 10.5. Serum Institute of India Pvt. Ltd.
  • 10.6. AstraZeneca
  • 10.7. Seqirus (CSL Limited)